Persistent Lower Respiratory Tract Inflammation Associated with Interstitial Lung Disease in Patients with Tropical Pulmonary Eosinophilia following Conventional Treatment with Diethylcarbamazine

1990 ◽  
Vol 142 (5) ◽  
pp. 1088-1092 ◽  
Author(s):  
W. N. Rom ◽  
V. K. Vijayan ◽  
M. J. Cornelius ◽  
V. Kumaraswami ◽  
R. Prabhakar ◽  
...  
Keyword(s):  
Interstitial Lung Disease ◽  
Respiratory Tract ◽  
Lung Disease ◽  
Lower Respiratory Tract ◽  
Conventional Treatment ◽  
Pulmonary Eosinophilia ◽  
Respiratory Tract Inflammation

Myositis-associated Interstitial Lung Disease: Predictors of Failure of Conventional Treatment and Response to Tacrolimus in a US Cohort

2017 ◽  
Vol 44 (11) ◽  
pp. 1612-1618 ◽  
Author(s):  
Niharika Sharma ◽  
Michael S. Putman ◽  
Rekha Vij ◽  
Mary E. Strek ◽  
Anisha Dua
Keyword(s):  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Clinical Characteristics ◽  
Conventional Treatment ◽  
Case Reports ◽  
Response To Therapy ◽  
Disease Modifying Antirheumatic Drugs ◽  
Antirheumatic Drugs ◽  
Small Series ◽  
The Mean

Objective.Patients with myositis-associated interstitial lung disease (MA-ILD) are often refractory to conventional treatment, and predicting their response to therapy is challenging. Recent case reports and small series suggest that tacrolimus may be useful in refractory cases.Methods.A retrospective cohort study of patients with MA-ILD comparing clinical characteristics between those who responded to or failed conventional treatment. In those who failed conventional treatment and received adjunctive tacrolimus, response to tacrolimus was measured by the improvement in myositis, ILD, and change in the dose of glucocorticoids.Results.Thirty-one of 54 patients (57%) responded to conventional treatment based on the predefined variables of improvement in myositis and/or ILD. Patients with polymyositis (PM)-ILD were more likely to respond to conventional treatment than those with dermatomyositis (DM)-ILD (67% vs 35%, p = 0.013). Twenty-three patients failed conventional treatment, 18 of whom subsequently received adjunctive tacrolimus. Ninety-four percent had improvements in ILD and 72% showed improvement in both myositis and ILD. The mean doses of prednisone decreased from baseline by 65% at 3–6 months (p = 0.002) and 81% at 1 year (p < 0.001).Conclusion.Patients with PM-ILD were more likely to respond to conventional treatment than patients with DM-ILD, but clinical characteristics and serology did not otherwise predict response to therapy. A majority of patients with MA-ILD refractory to conventional therapy improved while receiving tacrolimus and were able to decrease their dose of both glucocorticoids and other disease-modifying antirheumatic drugs.

STOSSTHERAPY IN ACUTE RESPIRATORY INFECTION IN CHILDREN

PEDIATRICS ◽  
1958 ◽  
Vol 22 (3) ◽  
pp. 421-421
Author(s):  
ALEX J. STEIGMAN
Keyword(s):  
Vitamin D ◽  
Tract Infection ◽  
Respiratory Tract ◽  
Acute Respiratory Infection ◽  
Lower Respiratory Tract ◽  
Recent Article ◽  
Conventional Treatment ◽  
Pneumococcal Pneumonia ◽  
Antibacterial Agents ◽  
Massive Dose

STOSSTHERAPY is a word of Germanic origin, Stoss referring to "a thrust" or "a push." The term has been used to describe a method of treating rickets with a single massive dose of vitamin D. In a recent article (Brit. M. J., 1:487, March 1, 1958) the author "thrusts" antibacterial agents at children and compares the results with conventional treatment by antibacterial agents over a period of some days. The chief contribution of this paper is to remind the reader that careful earlier studies showed that a single massive dose of sulfonamide can be curative of pneumococcal pneumonia in children, a fact established almost 20 years ago. In the debit side is the introduction of a burdensome word in a paper remarkably devoid of appropriate documentation. Between October, 1952, and October, 1954, 174 children with acute lower-respiratory-tract infection were treated at the Evelina Children's Hospital of Guy's Hospital, London, with penicillin by injection or oral sulfonamide, or a combination of both. The personal preferences of no less than 14 doctors who admitted these patients dictated the decisions regarding therapy.

scholarly journals Microbial communities in the respiratory tract of patients with interstitial lung disease

Thorax ◽  
2013 ◽  
Vol 68 (12) ◽  
pp. 1150-1156 ◽  
Author(s):  
Christian Garzoni ◽  
Silvio D Brugger ◽  
Weihong Qi ◽  
Sarah Wasmer ◽  
Alexia Cusini ◽  
...  
Keyword(s):  
Interstitial Lung Disease ◽  
Respiratory Tract ◽  
Lung Disease ◽  
Microbial Communities

Infection by the respiratory syncytial virus in infants and young children at high risk

2005 ◽  
Vol 15 (3) ◽  
pp. 256-265 ◽  
Author(s):  
Damien Bonnet ◽  
Achim A. Schmaltz ◽  
Timothy F. Feltes
Keyword(s):  
Respiratory Syncytial Virus ◽  
High Risk ◽  
Respiratory Tract ◽  
Lung Disease ◽  
Chronic Lung Disease ◽  
Lower Respiratory Tract ◽  
First Year ◽  
Syncytial Virus ◽  
First Year Of Life ◽  
Infants And Young Children

The respiratory syncytial virus is the most common cause of infection of the lower respiratory tract in infants and young children, and is the leading cause of hospitalisation and death due to viral illness during the first year of life. In otherwise healthy infants, the virus usually causes only mild respiratory illness, but premature babies and infants with chronic lung disease, those with congenitally malformed hearts, or those who are immunodeficient, are at increased risk of serious illness, hospitalisation, and death. Recent infection with the virus is also associated with increased postoperative complications after corrective surgery for congenitally malformed hearts. No effective vaccine is currently available, and treatment is limited to supportive therapy. Prevention in groups deemed to be at high-risk, therefore, is essential. In addition to measures for control of infection, prophylactic immunotherapy is indicated in selected patients. Palivizumab (Synagis®) is a monoclonal antibody indicated for the prevention of serious viral disease of the lower respiratory tract in premature infants, those with chronic lung disease, and those with haemodynamically significant congenital cardiac lesions. Palivizumab is given intramuscularly, usually as a monthly injection during the so-called “season”. In a recent international, randomised, double-blind, placebo-controlled trial in 1,287 children less than or equal to 2 years old with haemodynamically significant congenital cardiac malformations, prophylaxis achieved a relative reduction of 45 per cent in the incidence of antigen-confirmed viral-related hospitalisation, and reduced the duration of hospital stay by 56 per cent. National and international guidelines, therefore, now recommend routine prophylaxis in the first year of life in children with haemodynamically significant congenital cardiac disease.

scholarly journals Study protocol for a randomised, placebo-controlled, single-blind phase II study of the efficacy of morphine for dyspnoea in patients with interstitial lung disease (JORTC-PAL 15)

BMJ Open ◽  
2021 ◽  
Vol 11 (5) ◽  
pp. e043156
Author(s):  
Yoshinobu Matsuda ◽  
Tatsuya Morita ◽  
Shunsuke Oyamada ◽  
Keisuke Ariyoshi ◽  
Takuhiro Yamaguchi ◽  
...  
Keyword(s):  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Phase Ii ◽  
Conventional Treatment ◽  
Rating Scale ◽  
Phase Ii Study ◽  
Numerical Rating Scale ◽  
Morphine Injection ◽  
Numerical Rating ◽  
Ethical Approval

IntroductionDyspnoea is common in patients with interstitial lung disease (ILD) and often refractory to conventional treatment. Little is known about the efficacy of systemic morphine for dyspnoea in patients with ILD. The aim of this study is to estimate the efficacy of a single subcutaneous morphine injection for dyspnoea in patients with ILD.Methods and analysisWe will conduct a multicentre, prospective, randomised, placebo-controlled, single-blinded phase II study of a single subcutaneous morphine injection for dyspnoea in patients with ILD. In patients with ILD who have dyspnoea at rest refractory to conventional treatment will be eligible for participation in this study. The morphine dose will be 2 mg. The primary endpoint is changes in dyspnoea intensity from baseline to 60 min after treatment as measured using an 11-point Numerical Rating Scale and compared between the morphine and placebo groups.Ethics and disseminationEthical approval has been obtained by the Osaka City University Certified Review Board. The results of this study will be submitted for publication in an international peer-reviewed journal and the findings will be presented at international scientific conferences.Trial registration numberjRCTs051190030; pre-results.

Sign in / Sign up

Export Citation Format

Share Document